Enoxaparin sodium

Low molecular weight heparin, i.e. it has the same structural elements as unfractionated heparin but with a smaller average molecule size (<8000) The polysaccharide chains are composed of glucosamine and uronic acid building blocks (see structural formula under heparins), which are glycosidically linked to each other. Enoxaprin, like other low-molecular-weight heparins, binds and activates antithrombin III, which in turn inactivates coagulation factor Xa. As a result, less fibrin is formed from fibrinogen.

For prevention and treatment of thromboembolic diseases. Enoxaprin is suitable for the primary prevention of deep vein thrombosis in surgical and non-surgical procedures associated with a risk of thromboembolic events. Furthermore, it is used for the prophylaxis of thrombosis and anticoagulation in extracorporeal circulation during haemodialysis, for the therapy of deep vein thrombosis with and without pulmonary embolism.

Sensitization against heparins. With simultaneous intake of NSAIDs(diclofenac, metamizole or ibuprofen)

20 mg/day s.c. Primary prevention of deep vein thrombosis: peri- and postoperative in patients with low or medium risk of thromboembolic events.

40 mg/day s.c. Primary prophylaxis of deep vein thrombosis: peri- and post-operative in patients with a high risk of thromboembolic events, primary prophylaxis of deep vein thrombosis in non-surgical patients with a medium or high risk of thromboembolic events in acute serious internal diseases (e.g. heart failure NYHA III or IV, serious infections, respiratory diseases leading to immobilizing bedriddenness).

60 - 100 mg /day s.c. Therapy of deep vein thrombosis with and without pulmonary embolism, therapy of unstable angina pectoris and myocardial infarction.

Clexane®, Lovenox®

Enoxaparin is administered subcutaneously but not intramuscularly. Patients with renal insufficiency can be treated with enoxaparin at a reduced dose.